Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 19/20 | 0.59 |
| ▸ | DDB1 | Q16531 | 13/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.53 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30043335 | 0.90 | CRBN (0.70) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL10154012 | 0.90 | CRBN (0.70) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL24327157 | 0.82 | CRBN (0.81) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL24267535 | 0.82 | CRBN (0.81) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL25911683 | 0.82 | CRBN (0.58) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL14213199 | 0.81 | CRBN (0.80) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL4450512 | 0.80 | CRBN (0.69) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL31403507 | 0.80 | CRBN (0.69) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL28881272 | 0.80 | CRBN (0.62) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL23895931 | 0.79 | CRBN (0.57) | CRBNDDB1ALDH1A1CHRM2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017024318-A1 | TARGETED PROTEIN DEGRADATION TO ATTENUATE ADOPTIVE T-CELL THERAPY ASSOCIATED ADVERSE INFLAMMATORY RESPONSES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-02-09 | — | — | WO | disclosed |